Open Journal of Parkinson's Disease and Treatment Submit Manuscript


    • Volume/IssueClick here
    • Review ProcessDouble Blind
      • Publication lead time3 - 4 weeks
      • Indexing statusYes; Purview
      • Manuscript Processing ChargesClick here
      • Submission ChargesNo
      • Waiver policy for APCYes
      • Language of Full TextEnglish
      • Full-text formats availablePDF, HTML
    • Show +
    • Articles digitally archived in PORTICO
    • Permanent article identifierDOI (Digital Object Identifier) We provide DOI to all published papers to facilitate higher citation and classification of articles.
      Peertechz Publisher ID: 10.17352
    • Type of LicenseCreative Commons
      • Open AccessYes; Policy
      • Does the author retain unrestricted copyright?Yes
      • Does the author retain publishing rights?Yes
    • Show +

    Editorial Board

    Natascia De Lucia
    Department of Psychology
    Second University of Naples

    Research Interest: Neuropsychology,Neuropsychological Assessment, Cognitive,Memory, Executive Function.

    More Info.
    Department of Neurology
    National Taiwan University Hospital

    Research Interest: Parkinson's disease; Movement Disorders; Genetic study; Animal model; Drosophila.

    More Info.
    Nadia Soussi-Yanicostas
    Nationaldela Research Centre Paris Diderot University

    Research Interest: Neurodegenerative Diseases, Animal Model, Zebrafish (Danio Rerio), Microglia, Neuro-Inflammation, Tauopathies, Models Of Human Diseases, Scientific Interests, Bevaviour, Physiopathology Of Tauopathy, Molecular And Cellular Neuroscience, Wnt/ß-Catenin Signalling, New Drugs, Translational Research.  

    More Info.
    AQ Rana
    Movement Disorders Centre

    Research Interest: Call Neurology Section, Parkinson’s Disease, Non-Motor Symptoms Of Parkinson's Disease.  

    More Info.
    Keun A Chang
    Assistant Professor
    Department of Pharmacology
    Gachon University

    Research Interest: Neurodegenerative Disorder, Alzheimer's Disease, Parkinson's Disease, Stem Cell And Cognition.

    More Info.
    Diego Iacono
    Neuropathology Research Biomedical Research Institute of NJ Brinj

    Reseach Interest: Clinical and Experimental Neuropathology, Normal And Pathologic, Brain Aging, Bio-Brain Banking, Clinico-Pathologic Correlations, Animal And Cellular Models, Neuroproteomics, Neurogenomics, Quantitative Neuropathology, Neurostereology, Drug Discovery.  

    More Info.
    Sandip K Dash
    Neurology Apollo Hospital

    Research Interest: Alzheimer’s Disease, Lipo Protein A (Lpa) In Stroke Patients Among Local Population.

    More Info.
    Kamil Kuca
    International Relations University of Hradec Kralove
    Czech Republic

    Research Interest: Dementia, Drug Development, Nerve Agents, Treatment, Drug Design, Biomedicine.  

    More Info.
    Filiiz Altug
    Pamukkale University

    Research Interest: NEUROLOGİC REHABİLİTASYON, Stroke Rehabilitasyon, Parkinson’s Disease and Rehabilitation, Post Operatif Neck and Back Pain and Rehabilitation, Choronic Musculo Skeletal Pain and Rehabilitation.

    More Info.
    Minho Moon
    Assistant Professor
    Department of Biochemistry
    Konyang University

    Research Interest: Alzheimer ’S Disease, Parkinson’s Disease, Ghrelin, Nurr1, Adult Neurogenesis, Cognitive Behavior, Connectome, Natural Compounds.

    More Info.
    Oxana V Galzitskaya
    Bioinformatics Group Institute of Protein Research

    Research Interest: Intrinsically Disordered Proteins, Protein Folding, Protein Biophysics, Protein-Protein Interaction, Proteins, Protein Conformation, Protein Aggregation, Protein Stability, Protein Misfolding, Protein Dynamics, Protein Biochemistry, Protein Characterization, Structural Bioinformatics And Structural Biology, Aggregation, Protein Engineering, Computational Structural Biology, Prion Diseases, Structural Bioinformatics.

    More Info.
    Jifeng Guo
    Department of Neurology
    Central South University

    Research Interest: Parkinson's Disease; Neurodegenerative Disease; Clinical Phenotype; Genetics; Epigenetics; Pathogenesis.

    More Info.
    Kexin Liu
    Dalian Medical University

    Research Interest: Pharmacokinetics, Pharmacology, Drug-drug interaction, Transporter, Excretion, P-gp

    More Info.
    Neuropharmacology and Pain Research group
    University of Barcelona

    After some years of academic formation (I studied Pharmacy and a Master degree on Neuroscience from the University of Barcelona obtained in 2012) I was lucky to join the Neuropharmacology and Pain research lab in September 2012, where I started the Ph.D. training with a FPI Grant (Formación de Personal Investigador) from the Ministry of Economy and Competitiveness, under the supervision of Dr. Francisco Ciruela and Dr. Víctor Fernández-Dueñas.

    During this period my work was focused on deciphering the role of the Parkinson related GPR37, also known as PAEL receptor in the Central Nervous System, and looking for specific ligands for this orphan receptor. As GPR37 was an orphan receptor (which means that does not exist any ligand described that binds specifically to this receptor) we had to start building the house from the base. We produced recombinant proteins, specific antibodies and all the tools required to study this interesting and mysterious receptor implicated in the Parkinson’s neuropathological hallmarks. We also studied the interaction of this receptor with adenosine, dopamine and glutamate in different brain regions of interest such as striatum to find new potential treatments for Parkinson’s disease, and finally we focused on studying the potential use of the GPR37 as a biomarker in Parkinson’s disease (using both CSF and serum). We generated a homemade ELISA assay to detect GPR37 peptides in body fluids.

    As a result from all this work, I have participated in very different research projects, published more than 18 papers in peer-reviewed international journals and defend my work on international congress. Since 2018, I’ve been also collaborating with Laboratorios Dr. Esteve designing a new biosensor to facilitate Sigma1 receptor ligands screenings, a receptor implicated in different diseases, such as cocaine addiction, amnesia, pain, depression or Alzheimer’s disease.

    Research Interest: At this moment my research is focused in desciphering the role of different GPCRs in neurodegenerative diseases such as Parkinson’s disease, Alzheimer disease and Amyotrophic Lateral Sclerosis and Multiple Sclerosis.

    Grants: FPI grant, Eurolife Postdoctoral Mobility and Knowledge exchange


    List of Publications:

    1. Morató X; Rodrigo Antunes Cunha; Francisco Ciruela. GPR37 emerges as an important modulator of adenosinergic transmission in the striatum. Neural Regeneration Research. 2019.

    2. Morató X; Francisco Q Gonçalves; Joao Pedro Lopes; Olga Jauregui; Concepció Soler; Victor Fernández-Dueñas; Rodrigo Antunes Cunha; Francisco Ciruela. Chronic adenosine A2A receptor blockade induces locomotor sensitization and potentiates striatal LTD in GPR37 deficient mice. J Neurochem. 2019 Mar;148(6):796-809. doi: 10.1111/jnc.14653. Epub 2019 Jan 28.

    3. Luján R, Aguado C, Ciruela F, Arus XM, Martín-Belmonte A, Alfaro-Ruiz R, Martínez-Gómez J, de la Ossa L, Watanabe M, Adelman JP, Shigemoto R, Fukazawa Y. SK2 Channels Associate With mGlu1α Receptors and CaV2.1 Channels in Purkinje Cells. Front Cell Neurosci. 2018 Sep 19;12:311. doi: 10.3389/fncel.2018.00311. eCollection 2018.

    4. Gómez-Soler M, Cordobilla B, Morató X, Fernández-Dueñas V, Domingo JC, Ciruela F. Triglyceride Form of Docosahexaenoic Acid Mediates Neuroprotection in Experimental Parkinsonism. Front Neurosci. 2018 Aug 28;12:604. doi: 10.3389/fnins.2018.00604. eCollection 2018.

    5. Morató X, Luján R, Gonçalves N, Watanabe M, Altafaj X, Carvalho AL, Fernández-Dueñas V, Cunha RA, Ciruela F. Metabotropic glutamate type 5 receptor requires contactin-associated protein 1 to control memory formation. Hum Mol Genet. 2018 Oct 15;27(20):3528-3541. doi: 10.1093/hmg/ddy264.

    6. Eduard Tolosa; Teresa Botta-Orfila; Morató X; Calatayud C; Ferrer-Lorente R; Martí MJ; Fernández M; Gaig C; Raya Á; Consiglio A; Mario Ezquerra; Rubén Fernández Santiago. MicroRNA alterations in iPSC-derived dopaminergic neurons from Parkinson disease patients. Neurobiology of Aging. 5 - 32, pp. 283 - 291. Peter R. Rapp, 20/09/2018. ISSN 0197-4580.

    7. Morató X, Luján R, López-Cano M, Gandía J, Stagljar I, Watanabe M, Cunha RA, Fernández-Dueñas V, Ciruela F. The Parkinson's disease-associated GPR37 receptor interacts with striatal adenosine A2A receptor controlling its cell surface expression and function in vivo. Sci Rep. 2017 Aug 25; 7(1):9452.

    8. Kate Sokolina1#, Saranya Kittanakom1#, Jamie Snider, Max Kotlyar, Pascal Maurice, Jorge Gandía, Abla Benleulmi-Chaachoua, Kenjiro Tadagak, Victoria Wong, Ramy H. Malty, Viktor Deineko, Hiroyuki Aoki, Shahreen Amin, Laura Riley, Zhong Yao, Morató X, Sara Rahmati, Hiroyuki Kobayashi, Javier Menendez, Daniel Auerbach, Stephane Angers, Natasa Pržulj, Michel Bouvier, Mohan Babu, Francisco Ciruela, Ralf Jockers, Igor Jurisica, and Igor Stagljar. Systematic protein-protein interaction mapping for clinically-relevant human GPCRs. Molecular Systems Biology. 2017 Mar 15;13(3):918.

    9. Morató X, Marc López, P. M. Canas, R. A. Cunha, Francisco Ciruela. Brain membrane fractionation: An ex vivo approach to assess sub-synaptic protein localization. Journal of Visualized Experiments. J Vis Exp, May 2017, 12 (123).

    10. Paulo A. de Oliveira, James A.R. Dalton, Marc López-Cano, Adrià Ricarte, Morató X., Filipe C. Matheus, Andréia S. Cunha, Christa E. Müller, Reinaldo N. Takahashi, Víctor Fernández-Dueñas, Jesús Giraldo, Rui D. Prediger, Francisco Ciruela. Angiotensin II type 1/Adenosine A2A receptor oligomers: a novel target for tardive dyskinesia. Scientific reports. Sci Rep. 2017 May 12;7(1):1857.

    11. Víctor Fernández-Dueñas, Jhonny Azuaje, Morató X., Begoña Cordobilla, Joan Carles Domingo, Eddy Sotelo, Francisco Ciruela. Synthesis and characterization of a new bivalent ligand based on the combination of caffeine and docosahexaenoic acid. Molecules. Feb 2017. 27;22(3).

    12. Rial D, Morató X, Real JI, Gonçalves FQ, Stagljar I, Pereira FC, Fernández-Dueñas V, Cunha RA, Ciruela F. Parkinson's disease-associated GPR37 receptor regulates cocaine-mediated synaptic depression in corticostriatal synapses. Neurosci Lett. Jan 2017. 18;638:162-166. Page 6 of 7

    13. Lopes JP1, Morató X1, Souza C, Pinhal C, Machado NJ, Canas PM, Silva HB, Stagljar I, Gandía J, Fernández-Dueñas V, Luján R, Cunha RA, Ciruela F. The role of parkinson's disease-associated receptor GPR37 in the hippocampus: functional interplay with the adenosinergic system. J Neurochem. 2015 Jul; 134(1):135-46.

    14. Gandía J, Morató X, Stagljar I, Fernández-Dueñas V, Ciruela F. Adenosine A2A receptor-mediated control of pilocarpine-induced tremulous jaw movements is Parkinson's disease-associated GPR37 receptor-dependent. Behav Brain Res. 2015 Jul 15; 288:103-6.

    15. García-Negredo G, Soto D, Llorente J, Morató X, Galenkamp KM, Gómez-Soler M, Fernández-Dueñas V, Watanabe M, Adelman JP, Shigemoto R, Fukazawa Y, Luján R, Ciruela F. Coassembly and coupling of SK2 channels and mGlu5 receptors. J Neurosci. 2014 Oct 29;34(44):14793-802.

    16. Botta-Orfila T, Morató X, Compta Y, Lozano JJ, Falgàs N, Valldeoriola F, Pont-Sunyer C, Vilas D, Mengual L, Fernández M, Molinuevo JL, Antonell A, Martí MJ, Fernández-Santiago R, Ezquerra M. Identification of blood serum micro-RNAs associated with idiopathic and LRRK2 Parkinson's disease. J Neurosci Res. 2014 Aug;92(8):1071-7. doi: 10.1002/jnr.23377. Epub 2014 Mar 20.

    17. Fernández-Dueñas V, Gómez-Soler M, Morató X, Núñez F, Das A, Kumar TS, Jaumà S, Jacobson KA, Ciruela F. Dopamine D(2) receptor-mediated modulation of adenosine A(2A) receptor agonist binding within the A(2A)R/D(2)R oligomer framework. Neurochem Int. 2013 Jul;63(1):42-6.

    18. Gandía J, Fernández-Dueñas V, Morató X, Caltabiano G, González-Muñiz R, Pardo L, Stagljar I, Ciruela F. The Parkinson's disease-associated GPR37 receptor-mediated cytotoxicity is controlled by its intracellular cysteine-rich domain. J Neurochem. 2013.

    More Info.
    View more

    Accounting for behavioral deficits associated with damage in terms of cortical and subcortical information processes

    DOI Logo 10.17352/ojpdt.000014

    Published On: March 30, 2024 | Pages: 001 - 019

    Author(s): L Andrew Coward*

    ORCID Logo  0000-0003-1923-8038

    Abstract View Full Article View

    Parkinson’s disease dementia and dementia with lewy bodies differences and similarities

    DOI Logo 10.17352/ojpdt.000013

    Published On: April 14, 2023 | Pages: 001 - 013

    Author(s): Joanna Krasowska and Johan Lökk*
    Abstract View Full Article View

    The results of a clinical and neurophysiological study of the effectiveness of Parkon spray in the treatment of Parkinson’s Disease (PD)

    DOI Logo 10.17352/ojpdt.000012

    Published On: October 04, 2022 | Pages: 001 - 003

    Author(s): Gekht BM and Goldstein NI*
    Abstract View Full Article View

    Multi-center clinical study of Parkon® efficiency

    DOI Logo 10.17352/ojpdt.000011

    Published On: October 29, 2021 | Pages: 005 - 009

    Author(s): Fjodorova NE, Shtok VH, Gusev EI and Naum Goldstein*
    Abstract View Full Article View    

    How does medicine Parkon® affect the MPTP-induced oxidation stress and MAO systems of the rats brain

    DOI Logo 10.17352/ojpdt.000010

    Published On: May 25, 2021 | Pages: 001 - 004

    Author(s): N Goldstein*, A Kamensky, T Arshavskaya and R Goldstein
    Abstract View Full Article View    

    Cardiac Effects of Parkinson’s Diseasec

    DOI Logo 10.17352/ojpdt.000009

    Published On: December 19, 2020 | Pages: 006 - 007

    Author(s): Hüsnü Değirmenci*, Eftal Murat Bakirci and Hikmet Hamur
    Abstract View Full Article View    

    Parkon® in the treatment of multiple sclerosis. A pilot study

    DOI Logo 10.17352/ojpdt.000008

    Published On: August 07, 2020 | Pages: 001 - 005

    Author(s): Goldstein NI, Golubev VL and Goldstein RN*
    Abstract View Full Article View    

    A new technique to test the effect of cognition on standing balance in Parkinson’s disease

    DOI Logo 10.17352/ojpdt.000007

    Published On: September 20, 2019 | Pages: 006 - 013

    Author(s): Mayank Bhatt, Bhuvan Mahana, Jonathan J Marotta, Ji Hyun Ko, Douglas Everett Hobson and Tony Szturm*
    Abstract View Full Article View    

    Parkon as a treatment of the Parkinson’s disease

    DOI Logo 10.17352/ojpdt.000006

    Published On: March 19, 2019 | Pages: 001 - 005

    Author(s): Golubev VL, Sadekov PA, Pilipovich AA, Goldstein NI*
    Abstract View Full Article View    

    Genes involved in the development of Parkinson

    DOI Logo 10.17352/ojpdt.000005

    Published On: October 14, 2017 | Pages: 039 - 051

    Author(s): Diana Teixeira and Inês Lopes Cardoso*
    Abstract View Full Article View    


    Clients' voices